GlobeNewswire Inc.··Ascentage Pharma Group InternationalAscentage Pharma's Revenue Surges 90% on Olverembatinib, Lisaftoclax Growth
Ascentage Pharma reports 90% revenue growth to $82.1M in 2025, driven by Olverembatinib and newly launched Lisaftoclax, despite $177.7M net loss.
AAPGbiopharmaceuticalcancer therapy